Market News Comments

Bristol-Myers Squibb (BMY)

Bristol-Myers Squibb and ZymoGenetics presented final results from a Phase 1b clinical trial of PEG-Interferon lambda administered with ribavirin in relapsed and treatment-naïve hepatitis C virus (HCV) patients. Antiviral activity was observed at all dose levels tested.
“There is a strong need for additional options for hepatitis C patients,” said Brian Daniels, M.D., senior vice president, Global Development & Medical Affairs, Bristol-Myers Squibb. “We are pursuing this investigational pathway to address the fact that although current interferons have been the backbone of therapy with meaningful efficacy, they are often poorly tolerated, leading to dose reductions, poor compliance and avoidance of treatment.”

Nov 12 · 4:53:00 PM · Source: Business Wire · Related: ZymoGenetics Inc.
Track · email · face · Twitter · digg · COMMENTS
by Michael Oliveto

Enter your comment below and click Submit:

Copyright © 2010 MarketBeast.com.
All rights reserved.